MediWound Ltd. - Ordinary Shares (MDWD): Price and Financial Metrics


MediWound Ltd. - Ordinary Shares (MDWD): $1.79

-0.05 (-2.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MDWD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MDWD Stock Summary

  • MDWD has a higher market value than only 9.45% of US stocks; more precisely, its current market capitalization is $53,454,723.
  • The capital turnover (annual revenue relative to shareholder's equity) for MDWD is -5.19 -- better than merely 2.1% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 64.54 for MediWound Ltd; that's greater than it is for 99.55% of US stocks.
  • Stocks that are quantitatively similar to MDWD, based on their financial statements, market capitalization, and price volatility, are INSM, RDUS, INFN, EPZM, and ALBO.
  • Visit MDWD's SEC page to see the company's official filings. To visit the company's web site, go to www.mediwound.com.

MDWD Valuation Summary

  • MDWD's price/sales ratio is 3.9; this is 65.64% lower than that of the median Healthcare stock.
  • MDWD's price/sales ratio has moved NA NA over the prior 91 months.
  • MDWD's price/sales ratio has moved NA NA over the prior 91 months.

Below are key valuation metrics over time for MDWD.

Stock Date P/S P/B P/E EV/EBIT
MDWD 2021-08-31 3.9 46.8 -10.2 -10.5
MDWD 2021-08-30 3.9 46.0 -10.1 -10.2
MDWD 2021-08-27 3.9 45.9 -10.0 -10.2
MDWD 2021-08-26 3.9 45.9 -10.0 -10.2
MDWD 2021-08-25 3.9 46.7 -10.2 -10.4
MDWD 2021-08-24 3.9 46.9 -10.3 -10.5

MDWD Growth Metrics

    Its year over year cash and equivalents growth rate is now at 121.58%.
  • Its 3 year cash and equivalents growth rate is now at -20.96%.
  • Its 3 year net cashflow from operations growth rate is now at 42.59%.
Over the past 52 months, MDWD's revenue has gone up $21,367,000.

The table below shows MDWD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 23.763 -8.916 -13.551
2021-09-30 24.949 -10.033 -11.123
2021-06-30 25.202 -6.175 -9.685
2021-03-31 23.172 -8.005 -9.586
2020-12-31 21.763 -6.895 -9.196
2020-09-30 20.532 -5.873 -10.907

MDWD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDWD has a Quality Grade of D, ranking ahead of 14.08% of graded US stocks.
  • MDWD's asset turnover comes in at 0.824 -- ranking 31st of 681 Pharmaceutical Products stocks.
  • VRTX, CHUC, and AERI are the stocks whose asset turnover ratios are most correlated with MDWD.

The table below shows MDWD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.824 0.392 -1.189
2021-03-31 0.709 0.377 -0.788
2020-12-31 0.627 0.347 -0.555
2020-09-30 0.554 0.307 -0.464
2020-06-30 0.484 0.261 -0.326
2020-06-30 0.484 0.261 -0.326

MDWD Price Target

For more insight on analysts targets of MDWD, see our MDWD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.92 Average Broker Recommendation 1.33 (Strong Buy)

MDWD Stock Price Chart Interactive Chart >

Price chart for MDWD

MDWD Price/Volume Stats

Current price $1.79 52-week high $4.95
Prev. close $1.84 52-week low $1.21
Day low $1.78 Volume 40,200
Day high $1.85 Avg. volume 112,675
50-day MA $1.82 Dividend yield N/A
200-day MA $2.46 Market Cap 59.32M

MediWound Ltd. - Ordinary Shares (MDWD) Company Bio


MediWound Ltd. focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and others. The company was founded in 2000 and is based in Yavne, Israel.


MDWD Latest News Stream


Event/Time News Detail
Loading, please wait...

MDWD Latest Social Stream


Loading social stream, please wait...

View Full MDWD Social Stream

Latest MDWD News From Around the Web

Below are the latest news stories about MediWound Ltd that investors may wish to consider to help them evaluate MDWD as an investment opportunity.

Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army

Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field CareYAVNE, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair and regeneration, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound a $1.7 million research project for the devel

Yahoo | February 17, 2022

MediWound to Present at Upcoming Investor Conferences in February

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceDate:Wednesday, February 16, 2022Time:8:30 am ETFormat:Fireside ChatRegistration Link:C

Yahoo | February 14, 2022

MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application Resubmission

The Biomedical Advanced Research and Development Authority (BARDA) will provide supplemental funding of million to MediWound Ltd (NASDAQ: MDWD) to Support NexoBrid application resubmission and the expanded access treatment protocol. The Company continues to advance the preparation of the FDA Marketing application resubmission anticipated in mid-2022. MediWound was awarded its first BARDA contract to treat thermal burn injuries in 2015. That first BARDA contract, valued at up to $168 million, sup

Yahoo | February 10, 2022

MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol

YAVNE, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has expanded its awarded contract with MediWound by providing sup

Yahoo | February 10, 2022

Read More 'MDWD' Stories Here

MDWD Price Returns

1-mo -3.76%
3-mo -12.25%
6-mo -38.06%
1-year -54.68%
3-year -44.92%
5-year -72.67%
YTD -24.15%
2021 -36.22%
2020 19.35%
2019 -23.65%
2018 -8.76%
2017 -2.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5082 seconds.